A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines
BACKGROUND: In 2001, two hexavalent vaccines were licensed in Italy (Hexavac, Infanrix Hexa), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the market authorization of Hexavac was precautionary suspended by EMEA, because of doubts on long-term protection against hepatitis B virus. The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine.
METHODS: Participant children were enrolled concomitantly with the offering of anti-polio booster dose, in the third year of life. Anti-HBs titers were determined on capillary blood samples. A booster dose of hepatitis B vaccine was administered to children with anti-HBs titers < 10 mIU/ml, with the monovalent precursor product of the previously received hexavalent vaccine. HBsAb titers were tested again one month after the booster.
RESULTS: Sera from 113 children previously vaccinated with Hexavac, and from 124 vaccinated with Infanrix Hexa were tested for anti-HBs. Titers were > or = 10 mIU/ml in 69% and 96% (p < 0,0001) respectively. The proportion of children with titers > or = 100 mIU/ml did also significantly differ among groups (27% and 78%; p < 0,0001).Post-booster, 93% of children achieved titers > or = 10 mIU/ml, with no significant difference by vaccine group.
DISCUSSION: Fifteen months after third dose administration, a significant difference in anti-HBs titers was noted in the two vaccine groups considered. Monovalent hepatitis B vaccine administration in 3-year old children induced a proper booster response, confirming that immunologic memory persists in children with anti-HBs titers < 10 mIU/ml. However, long-term persistence of HBV protection after hexavalent vaccines administration should be further evaluated over time.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2008 |
|---|---|
| Erschienen: |
2008 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 8(2008) vom: 28. Juli, Seite 100 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giambi, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comparative Study |
|---|
| Anmerkungen: |
Date Completed 06.10.2008 Date Revised 20.10.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/1471-2334-8-100 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM181216604 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM181216604 | ||
| 003 | DE-627 | ||
| 005 | 20231223160844.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2008 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1471-2334-8-100 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0604.xml |
| 035 | |a (DE-627)NLM181216604 | ||
| 035 | |a (NLM)18662386 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giambi, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines |
| 264 | 1 | |c 2008 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.10.2008 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: In 2001, two hexavalent vaccines were licensed in Italy (Hexavac, Infanrix Hexa), and since 2002 were extensively used for primary immunization in the first year of life (at 3, 5, 11/12 months of age). In 2005, the market authorization of Hexavac was precautionary suspended by EMEA, because of doubts on long-term protection against hepatitis B virus. The objectives of this study were to evaluate the persistence of antibodies to anti-HBs, in children in the third year of life, and to investigate the response to a booster dose of hepatitis B vaccine | ||
| 520 | |a METHODS: Participant children were enrolled concomitantly with the offering of anti-polio booster dose, in the third year of life. Anti-HBs titers were determined on capillary blood samples. A booster dose of hepatitis B vaccine was administered to children with anti-HBs titers < 10 mIU/ml, with the monovalent precursor product of the previously received hexavalent vaccine. HBsAb titers were tested again one month after the booster | ||
| 520 | |a RESULTS: Sera from 113 children previously vaccinated with Hexavac, and from 124 vaccinated with Infanrix Hexa were tested for anti-HBs. Titers were > or = 10 mIU/ml in 69% and 96% (p < 0,0001) respectively. The proportion of children with titers > or = 100 mIU/ml did also significantly differ among groups (27% and 78%; p < 0,0001).Post-booster, 93% of children achieved titers > or = 10 mIU/ml, with no significant difference by vaccine group | ||
| 520 | |a DISCUSSION: Fifteen months after third dose administration, a significant difference in anti-HBs titers was noted in the two vaccine groups considered. Monovalent hepatitis B vaccine administration in 3-year old children induced a proper booster response, confirming that immunologic memory persists in children with anti-HBs titers < 10 mIU/ml. However, long-term persistence of HBV protection after hexavalent vaccines administration should be further evaluated over time | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Diphtheria-Tetanus-Pertussis Vaccine |2 NLM | |
| 650 | 7 | |a Hepatitis B Antibodies |2 NLM | |
| 650 | 7 | |a Hepatitis B Vaccines |2 NLM | |
| 650 | 7 | |a Hexavac |2 NLM | |
| 650 | 7 | |a Poliovirus Vaccine, Inactivated |2 NLM | |
| 650 | 7 | |a Vaccines, Combined |2 NLM | |
| 700 | 1 | |a Bella, Antonino |e verfasserin |4 aut | |
| 700 | 1 | |a Barale, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Montù, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Marchisio, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Oddone, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Zito, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Rapicetta, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Chionne, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Madonna, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Ciofi degli Atti, Marta L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 8(2008) vom: 28. Juli, Seite 100 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2008 |g day:28 |g month:07 |g pages:100 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/1471-2334-8-100 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2008 |b 28 |c 07 |h 100 | ||